Akari Therapeutics Plc Files 8-K

Ticker: AKTX · Form: 8-K · Filed: Jan 13, 2025 · CIK: 1541157

Sentiment: neutral

Topics: regulatory-disclosure, 8-K, company-information

Related Tickers: AKTX

TL;DR

AKTX filed an 8-K on Jan 13, 2025 - standard disclosure.

AI Summary

Akari Therapeutics Plc announced a Regulation FD Disclosure on January 13, 2025. The company, formerly known as Celsus Therapeutics Plc and Morria Biopharmaceuticals PLC, is incorporated in England and Wales and has its principal executive offices in Boston, MA. The filing is a current report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.

Why It Matters

This 8-K filing indicates a regulatory disclosure event for Akari Therapeutics Plc, providing transparency to investors about the company's compliance and reporting status.

Risk Assessment

Risk Level: low — This filing is a routine 8-K current report, indicating standard regulatory compliance rather than a specific material event.

Key Numbers

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing?

This 8-K filing serves as a current report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, indicating a Regulation FD Disclosure.

When was the earliest event reported in this filing?

The earliest event reported in this filing occurred on January 13, 2025.

What are the former names of Akari Therapeutics Plc?

Akari Therapeutics Plc was formerly known as Celsus Therapeutics Plc and Morria Biopharmaceuticals PLC.

Where are Akari Therapeutics Plc's principal executive offices located?

Akari Therapeutics Plc's principal executive offices are located at 22 Boston Wharf Road, FL 7, Boston, MA 02210.

What is the SEC file number for Akari Therapeutics Plc?

The SEC file number for Akari Therapeutics Plc is 001-36288.

Filing Stats: 532 words · 2 min read · ~2 pages · Grade level 10.3 · Accepted 2025-01-13 08:00:15

Key Financial Figures

Filing Documents

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On January 13, 2025, Akari Therapeutics, Plc (the "Company") updated information reflected in a slide presentation, which is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. Representatives of the Company will use the updated presentation in various meetings from time to time. The information contained in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act, or the Exchange Act, except as expressly set forth by specific reference in such filing.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Corporate Presentation 104 The cover page from this Current Report on Form 8-K, formatted in Inline XBRL.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Akari Therapeutics, Plc Date: January 13, 2025 By: /s/ Samir R. Patel, M.D. Samir R. Patel, M.D. President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing